OverviewSuggest Edit

MacroGenics, Inc. is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops new therapeutic product candidates using its antibody-based technology platforms and also in partnership with other biopharmaceutical companies. MacroGenics has a pipeline of product candidates in human clinical testing, primarily against various cancers. These include two product candidates developed using Fc Optimization platform, namely margetuximab, an antibody for the treatment of certain types of metastatic breast cancers and gastroesophageal cancers, and MGA271, an antibody to impact various tumors through multiple potential mechanisms of action. In addition, the Company has created different product candidates based on Dual-Affinity Re-Targetingr (DART) platform.

TypePublic
Founded2000
HQRockville, MD, US
Websitemacrogenics.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Feb 2020)384(+6%)
Job Openings41
Revenue (FY, 2020)$104.9 M(+64%)
Share Price (May 2021)$29.5(+3%)
Cybersecurity ratingBMore

Key People/Management at MacroGenics

Scott Koenig

Scott Koenig

President and CEO and Director
Paulo Costa

Paulo Costa

Chairman
James Karrels

James Karrels

Senior Vice President, Chief Financial Officer and Secretary
Karen Ferrante

Karen Ferrante

Director
Ezio Bonvini

Ezio Bonvini

Senior Vice President, Research and Chief Scientific Officer
Stephen Eck

Stephen Eck

Senior Vice President, Clinical Development & Chief Medical Officer
Show more

MacroGenics Office Locations

MacroGenics has offices in Rockville and Brisbane
Rockville, MD, US (HQ)
9640 Medical Center Dr
Brisbane, CA, US
3280 Bayshore Blvd #200
Rockville, MD, US
15235 Shady Grove Rd
Show all (3)

MacroGenics Financials and Metrics

MacroGenics Revenue

MacroGenics's revenue was reported to be $104.88 m in FY, 2020
USD

Revenue (Q1, 2021)

16.9m

Gross profit (Q1, 2021)

16.9m

Gross profit margin (Q1, 2021), %

99.9%

Net income (Q1, 2021)

(51.3m)

EBIT (Q1, 2021)

(51.3m)

Market capitalization (14-May-2021)

1.8b

Closing stock price (14-May-2021)

29.5

Cash (31-Mar-2021)

218.5m

EV

1.6b
MacroGenics's current market capitalization is $1.8 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

58.0m47.8m100.9m91.9m157.7m60.1m64.2m104.9m

Revenue growth, %

(18%)111%(9%)

General and administrative expense

11.1m15.9m22.8m29.8m32.7m40.5m46.1m42.7m

R&D expense

46.6m70.2m98.3m122.1m147.2m190.8m195.3m193.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

20.2m14.7m9.2m18.4m71.3m6.7m14.7m2.8m80.7m3.3m2.1m1.7m1.7m4.7m18.8m20.8m9.7m10.0m18.0m13.7m15.6m17.4m16.9m

Cost of goods sold

17.0k

Gross profit

16.9m

Gross profit Margin, %

100%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

116.5m157.6m196.2m84.1m211.7m126.5m181.1m

Accounts Receivable

2.0m2.9m1.2m2.8m13.6m12.7m23.1m

Prepaid Expenses

971.7k4.2m1.8m3.2m11.3m17.0m

Inventories

Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

33.6m198.7m194.0m179.2m263.1m235.0m365.8m152.0m62.3m109.9m40.5m116.6m90.9m200.4m238.7m201.8m238.6m180.3m156.6m93.1m196.5m201.6m218.5m

Accounts Receivable

2.3m1.7m2.6m5.3m1.7m4.3m2.7m2.5m78.4m3.0m2.1m2.0m2.2m7.3m17.8m21.0m6.1m5.6m9.5m11.8m19.2m18.8m7.1m

Prepaid Expenses

2.1m2.5m3.6m3.1m2.0m1.7m3.8m1.3m5.0m4.0m3.3m3.3m3.2m8.3m9.6m12.0m12.6m8.2m10.6m18.2m

Inventories

6.2m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(260.8k)(38.3m)(20.1m)(58.5m)(19.6m)(171.5m)(151.8m)(129.7m)

Depreciation and Amortization

1.2m1.8m2.9m7.6m7.2m8.3m10.8m12.0m

Accounts Payable

(570.1k)(1.5m)(163.0k)2.2m(1.5m)1.6m787.0k3.7m

Cash From Operating Activities

(14.2m)(32.8m)(13.7m)(43.7m)14.4m(153.2m)(134.3m)(111.9m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

2.9m(3.1m)(15.4m)(19.3m)45.1m23.8m8.3m(30.4m)10.1m(23.7m)(37.7m)(78.3m)(125.4m)(49.5m)(92.8m)(126.8m)(45.0m)(76.8m)(121.4m)(44.7m)(91.6m)(127.7m)(51.3m)

Depreciation and Amortization

834.6k398.2k835.0k1.3m546.0k1.2m1.7m1.8m3.6m5.6m2.0m4.0m5.9m1.3m2.5m5.3m2.9m5.5m8.1m2.8m6.1m9.1m2.7m

Inventories

(6.2m)

Accounts Payable

(1.9m)2.0m808.0k1.2m(225.0k)184.0k872.0k(388.0k)(355.0k)(133.0k)(2.2m)(2.0m)(2.1m)7.8m(684.0k)(1.5m)(2.5m)(2.6m)(913.0k)(2.3m)(1.5m)137.0k1.8m
USDQ3, 2013

Financial Leverage

-10.4 x
Show all financial metrics

MacroGenics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

MacroGenics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

MacroGenics Online and Social Media Presence

Embed Graph

MacroGenics News and Updates

MacroGenics Announces Date of First Quarter 2021 Financial Results Conference Call

ROCKVILLE, MD, April 19, 2021 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial resu…

Global Acute Myeloid Leukemia (AML) Disease Market Report 2021 Featuring Apollomics, Astellas, BerGenBio, Chimerix, Daiichi Sankyo, Forma, GlycoMimetics, Kiadis, MacroGenics, Medigene & Piramal

DUBLIN, April 14, 2021 /PRNewswire/ -- The "Disease Analysis: Acute Myeloid Leukemia (AML)" report has been added to ResearchAndMarkets.com's offering. AML is a type of heterogeneous hematological malignancy that originates from immature white blood cells (blasts) in the bone marrow,...

MacroGenics Announces Presentations at the 2021 AACR Annual Meeting

ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American Association for Ca…

MacroGenics Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call

ROCKVILLE, MD, Feb. 18, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial resu…

MacroGenics Names Federica O’Brien to its Board of Directors

ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Federica “Freddi” O’Brien, Pre…

MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte

ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that a $10 million milestone has been achieved re…
Show more

MacroGenics Blogs

MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results

MARGENZA™ launched in mid-March Upcoming poster presentation of MGC018 initial Phase 1 clinical data at ASCO Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md. , April 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing

MacroGenics Provides Update on Corporate Progress and 2020 Financial Results

MacroGenics Provides Update on Corporate Progress and 2020 Financial Results Content Import Thu, 02/25/2021 - 16:04 MacroGenics Provides Update on Corporate Progress and 2020 Financial Results Feb 25, 2021 This release is a backfill from a News Wire …

MacroGenics Announces MGD019 Publication in Cell Reports Medicine

MacroGenics Announces MGD019 Publication in Cell Reports Medicine Content Import Tue, 12/22/2020 - 11:35 MacroGenics Announces MGD019 Publication in Cell Reports Medicine Dec 22, 2020 This release is a backfill from a News Wire General …

MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® ( trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial MARGENZA is approved, in combination with chemotherapy, for the treatment of

MacroGenics Presents Tebotelimab Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma at the 2020 ASH Annual Meeting

53.8% ORR in relapsed/refractory DLBCL patients  Preliminary duration of response of up to 168 days observed, with six of seven ongoing responses as of cut-off date  ROCKVILLE, MD , Dec. 07, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company

MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference Call

MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference Call Content Import Wed, 10/28/2020 - 16:31 MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference Call Oct 28, 2020 This release is a backfill from a News Wir…
Show more

MacroGenics Frequently Asked Questions

  • When was MacroGenics founded?

    MacroGenics was founded in 2000.

  • Who are MacroGenics key executives?

    MacroGenics's key executives are Scott Koenig, Paulo Costa and James Karrels.

  • How many employees does MacroGenics have?

    MacroGenics has 384 employees.

  • What is MacroGenics revenue?

    Latest MacroGenics annual revenue is $104.9 m.

  • What is MacroGenics revenue per employee?

    Latest MacroGenics revenue per employee is $273.1 k.

  • Who are MacroGenics competitors?

    Competitors of MacroGenics include Chiesi Group, HEC Pharm and Cadila Pharmaceuticals.

  • Where is MacroGenics headquarters?

    MacroGenics headquarters is located at 9640 Medical Center Dr, Rockville.

  • Where are MacroGenics offices?

    MacroGenics has offices in Rockville and Brisbane.

  • How many offices does MacroGenics have?

    MacroGenics has 3 offices.